ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.58
+0.67 (8.47%)
Sep 17, 2026, 10:39 AM EDT - Market open
ImmunityBio Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 165.79 | 113.29 | 14.75 | 0.62 | 0.24 | 0.93 |
Revenue Growth | 192.92% | 668.32% | 2270.58% | 159.17% | -74.30% | 54.38% |
Gross Profit Gross Profit Growth | 164.7 | 112.54 | 14.75 | 0.62 | 0.24 | 0.93 |
Operating Income Operating Income Growth | -251.8 | -256.03 | -344.18 | -361.36 | -350.67 | -317.42 |
Net Income Net Income Growth | -992.36 | -351.4 | -413.56 | -583.2 | -416.57 | -346.79 |
Earnings Per Share EPS Growth | -0.99 | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Product Product Growth | 164.89 | 112.98 | 14.15 | - | - | - |
Other Other Growth | 0.9 | 0.31 | 0.6 | 0.62 | 0.24 | 0.93 |
Revenue (Total) Revenue (Total) Growth | 165.79 | 113.29 | 14.75 | 0.62 | 0.24 | 0.93 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 357.37 | 242.82 | 149.81 | 267.35 | 108.02 | 317.94 |
Total Debt Total Debt Growth | 1,228 | 844.72 | 789.82 | 883.68 | 725.33 | 648.26 |
Net Cash (Debt) Net Cash Growth | -871.03 | -601.9 | -640.01 | -616.32 | -617.31 | -330.32 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.87 | -0.65 | -0.91 | -1.21 | -1.54 | -0.85 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -281.14 | -304.94 | -391.24 | -366.76 | -337.51 | -274.42 |
Capital Expenditures CapEx Growth | -6.94 | -3.85 | -6.89 | -30.58 | -78.16 | -33.56 |
Free Cash Flow Free Cash Flow Growth | -288.07 | -308.78 | -398.12 | -397.34 | -415.67 | -307.98 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 99.34% | 99.33% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -151.88% | -226.00% | -2334.23% | -58097.11% | -146111.67% | -33985.44% |
Pretax Margin | -598.69% | -310.37% | -2805.32% | -93873.31% | -173869.17% | -37456.00% |
Profit Margin | -598.55% | -310.18% | -2804.77% | -93761.41% | -173569.58% | -37129.55% |
FCF Margin | -173.76% | -272.56% | -2700.06% | -63881.19% | -173196.25% | -32974.52% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 50.57 | 17.22 | 126.77 | 5388.88 | 8648.47 | 2589.53 |